Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation

Julia Meyer, PhD, Maximillian Schönung, Christian Flotho, MD PhD, Adam B. Olshen, PhD, Mark Hartmann, PhD, Christoph Plass, PhD, Yusuke Okuno, MD PhD, Yoshiyuki Takahashi, MD PhD, Norihiro Murakami, MD PhD, Manabu Wakamatsu, MD, Mignon L. Loh, MD, Charlotte M. Niemeyer, MD, Hideki Muramatsu, MD PhD, Daniel B. Lipka, MD, Elliot Stieglitz, MD

Blood (2019) 134 (Supplement_1): 1693.

https://doi.org/10.1182/blood-2019-131279

Published: 2019

Journal Articles

No Evidence for Hematopoietic Stem Cell Self-Renewal in-Vivo Following Inflammatory Challenge

Blood (2019) 134 (Supplement_1): 456.

https://doi.org/10.1182/blood-2019-125744

Published: 2019

Journal Articles

Deconvolution of Hematopoietic Commitment Decisions By Genome-Wide Analysis of Progressive DNA Methylation Changes

Blood (2019) 134 (Supplement_1): 1179.

https://doi.org/10.1182/blood-2019-124429

Published: 2019

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Claire N. Harrison, Jean-Jacques Kiladjian, MD PhD, Florian H. Heidel, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, MD, Daniel B. Lipka, MD, Suddhasatta Acharyya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Susan Ide, PhD, Tracy Liu, Song Mu, PhD, Vincent Ribrag, MD

Blood (2015) 126 (23): 4060.

https://doi.org/10.1182/blood.V126.23.4060.4060

Published: 2015

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 711.

https://doi.org/10.1182/blood.V124.21.711.711

Published: 2014

Journal Articles

Epo-Induced Erythroid Maturation Is Dependent On Plcγ1 Signalling

Tina M Schnoeder, PhD, Patricia Arreba-Tutusaus, MSc, Inga Griehl, cand. med., Lars Bullinger, MD, PhD, Konstanze Doehner, MD, Christoph Plass, PhD, Daniel B Lipka, MD, Florian H Heidel, MD, Thomas Fischer, M.D. Ph.D.

Blood (2013) 122 (21): 1182.

https://doi.org/10.1182/blood.V122.21.1182.1182

Published: 2013

Journal Articles

Identification of Phospholipase C Gamma 1 As a Key Regulator of Erythropoiesis

Tina M Schnoeder, PhD, Patricia Arreba-Tutusaus, MSc, Inga Griehl, cand. med., Daniel B Lipka, MD, Florian H Heidel, MD, Thomas Fischer, MD

Blood (2012) 120 (21): 4744.

https://doi.org/10.1182/blood.V120.21.4744.4744

Published: 2012

Journal Articles

FLT3-Kinase Inhibitors Quizartinib and Midostaurin Do Not Impair T-Cell Reactivity and Activation

Denise Wolleschak, MD, Thomas S. Mack, MSc, Florian Perner, Tina M Schnoeder, PhD, Marie-Christine Wagner, Stefanie Kliche, PhD, Burkhart Schraven, Satish Ranjan, Berend H. Isermann, MD, Daniel B. Lipka, MD, Thomas Fischer, MD, Florian H Heidel, MD

Blood (2012) 120 (21): 1045.

https://doi.org/10.1182/blood.V120.21.1045.1045

Published: 2012

Journal Articles

A Novel Paradigm In Pharmacodynamics of Tyrosine Kinase Inhibitors: Pulse Treatment Induced Apoptosis Is Mediated by Intracellular Retention

Marie-Christine Wagner, Marek Dziadosz, Tina Schnoeder, PhD, Florian H. Heidel, MD, Thomas Fischer, MD, Daniel B. Lipka, MD

Blood (2010) 116 (21): 1828.

https://doi.org/10.1182/blood.V116.21.1828.1828

Published: 2010

Journal Articles

Different FLT3 -ITD Integration Sites Are Associated with Differential Sensitivity to Tyrosine Kinase Inhibitors (TKI) In Vitro.

Thomas S. Mack, Marie-Christine Blum, Thomas Kindler, Daniel B. Lipka, MD, Florian H. Heidel, MD, Thomas Fischer, MD

Blood (2010) 116 (21): 1709.

https://doi.org/10.1182/blood.V116.21.1709.1709

Published: 2010

Journal Articles

Analysis of Differentially Activated Signaling Pathways in Myeloproliferative Disease Using Kinomics Chip Profiling

Daniel B Lipka, MD, Marie-Christine Blum, MSc, Florian H Heidel, MD, Thomas Kindler, M.D., Thomas Fischer, MD

Blood (2008) 112 (11): 3723.

https://doi.org/10.1182/blood.V112.11.3723.3723

Published: 2008

Journal Articles

The Role of Mcl-1 Expression and Phosphorlyation in Resistance to Chemotherapy and Kinase Inhibitors in FLT3-ITD-Positive Acute Myeloid Leukemia (AML)

Florian H Heidel, MD, Henning Schulze-Bergkamen, MD, Binje Vick, Daniel B Lipka, MD, Fian K Mirea, Toni Urbanik, Joseph T Opferman, PhD, Thomas Fischer, MD

Blood (2008) 112 (11): 220.

https://doi.org/10.1182/blood.V112.11.220.220

Published: 2008

Journal Articles

3,4-Diarylmaleimides Effectively Inhibit Proliferation of FLT3-ITD-Positive Leukemic Cells, Induce Apoptosis and Show Additive Effects in Combination with Chemotherapeutic Drugs.

Florian H. Heidel, MD, Daniel B. Lipka, MD, Fian K. Mirea, Boyka Markova, PhD, Christian Peifer, PhD, Jan-Peter Kramp, PhD, Stanislav Plutizki, Christoph Huber, MD, Gerd Dannhardt, PhD, Thomas Fischer, MD

Blood (2007) 110 (11): 1605.

https://doi.org/10.1182/blood.V110.11.1605.1605

Published: 2007

Journal Articles

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

Daniel B. Lipka, MD, Linda S. Hoffmann, MSc, Florian Heidel, MD, Boyka Markova, PhD, Stefan Kasper, MD, Frank Breitenbuecher, PhD, Thomas Kindler, MD, Ross Levine, MD, Joseph Elliot, PhD, Christoph Huber, MD, Thomas Fischer, MD

Blood (2007) 110 (11): 3544.

https://doi.org/10.1182/blood.V110.11.3544.3544

Published: 2007

NARROW

DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation

No Evidence for Hematopoietic Stem Cell Self-Renewal in-Vivo Following Inflammatory Challenge

Deconvolution of Hematopoietic Commitment Decisions By Genome-Wide Analysis of Progressive DNA Methylation Changes

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Epo-Induced Erythroid Maturation Is Dependent On Plcγ1 Signalling

Identification of Phospholipase C Gamma 1 As a Key Regulator of Erythropoiesis

FLT3-Kinase Inhibitors Quizartinib and Midostaurin Do Not Impair T-Cell Reactivity and Activation

A Novel Paradigm In Pharmacodynamics of Tyrosine Kinase Inhibitors: Pulse Treatment Induced Apoptosis Is Mediated by Intracellular Retention

Different FLT3 -ITD Integration Sites Are Associated with Differential Sensitivity to Tyrosine Kinase Inhibitors (TKI) In Vitro.

Analysis of Differentially Activated Signaling Pathways in Myeloproliferative Disease Using Kinomics Chip Profiling

The Role of Mcl-1 Expression and Phosphorlyation in Resistance to Chemotherapy and Kinase Inhibitors in FLT3-ITD-Positive Acute Myeloid Leukemia (AML)

3,4-Diarylmaleimides Effectively Inhibit Proliferation of FLT3-ITD-Positive Leukemic Cells, Induce Apoptosis and Show Additive Effects in Combination with Chemotherapeutic Drugs.

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only